GLOBOVAX Trademark

Trademark Overview


On Tuesday, January 19, 2016, a trademark application was filed for GLOBOVAX with the United States Patent and Trademark Office. The USPTO has given the GLOBOVAX trademark a serial number of 86879881. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, June 12, 2018. This trademark is owned by OBI PHARMA, INC.. The GLOBOVAX trademark is filed in the Pharmaceutical Products category with the following description:

adjuvants for medical purposes; amino acids for medical purposes; amino acids for veterinary purposes; soap-bark tree, quillaja, quillais and Quillaja saponaria Molina barks for pharmaceutical purposes; biological preparations for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; biological preparations for veterinary purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; chemical reagents for medical or veterinary purposes; chemical preparations for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemical preparations for pharmaceutical purposes, namely, for the di...
globovax

General Information


Serial Number86879881
Word MarkGLOBOVAX
Filing DateTuesday, January 19, 2016
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, June 12, 2018
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 6, 2016

Trademark Statements


Goods and Servicesadjuvants for medical purposes; amino acids for medical purposes; amino acids for veterinary purposes; soap-bark tree, quillaja, quillais and Quillaja saponaria Molina barks for pharmaceutical purposes; biological preparations for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; biological preparations for veterinary purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; chemical reagents for medical or veterinary purposes; chemical preparations for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemical preparations for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemical preparations for veterinary purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; chemico-pharmaceutical preparations for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; drugs for medical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; glucose for medical purposes; milk sugar for pharmaceutical purposes; lactose for pharmaceutical purposes; medicinal roots; medicinal herbs; medicinal oils; medicinal infusions for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; medicines for human purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; medicines for veterinary purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; pharmaceutical preparations for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; phosphates for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; potassium salts for medical purposes; reagent paper for medical or veterinary purposes; mineral salts for medical purposes; sodium salts for medical purposes; sugar for medical purposes; vaccines; veterinary preparations for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; yeast for pharmaceutical purposes; acetates for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; acids for pharmaceutical purposes, namely, for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; alginates for pharmaceutical purposes; blood for medical purposes; blood plasma; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; diastase for medical purposes; enzyme preparations for medical purposes; enzymes for medical purposes; ferments for pharmaceutical purposes; medicated pastilles for pharmaceutical purposes; medicated lozenges for pharmaceutical purposes; flour for pharmaceutical purposes; meal for pharmaceutical purposes; hormones for medical purposes; milk ferments for pharmaceutical purposes; cultures of microorganisms for medical and veterinary use; preparations of microorganisms for medical and veterinary use, namely, nutritive substances for microorganisms for medical and veterinary use; serotherapeutic medicines for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; medicated serums for the diagnosis, monitoring, treatment and prevention of immune system related diseases, cancer and infectious diseases; stem cells for medical purposes; anti-cancer preparations; adjuvants for use with vaccines; biological preparations for the treatment of cancer. drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; ferments for medical or veterinary use; human vaccine preparations; medicinal preparations for the treatment of infectious diseases and for use in oncology; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for the prevention and treatment of cancer; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; reagents for medical use; vaccine adjuvants; vaccine preparations; vaccine stabilizers
Pseudo MarkGLOBALL VAX

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 25, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameOBI PHARMA, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTaipei 11503
TW

Party NameOBI PHARMA, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTaipei 11503
TW

Trademark Events


Event DateEvent Description
Tuesday, June 12, 2018ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Tuesday, June 12, 2018ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, February 20, 2018ASSIGNED TO EXAMINER
Tuesday, November 14, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 14, 2017NON-FINAL ACTION E-MAILED
Tuesday, November 14, 2017NON-FINAL ACTION WRITTEN
Tuesday, November 14, 2017CASE RETURNED TO EXAMINATION
Friday, October 27, 2017NOTICE OF ALLOWANCE CANCELLED
Tuesday, November 14, 2017PREVIOUS ALLOWANCE COUNT WITHDRAWN
Thursday, November 2, 2017ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED
Thursday, November 2, 2017PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Tuesday, October 31, 2017ASSIGNED TO PETITION STAFF
Tuesday, October 31, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 27, 2017EXTENSION 2 GRANTED
Friday, October 27, 2017EXTENSION 2 FILED
Friday, October 27, 2017TEAS EXTENSION RECEIVED
Monday, October 9, 2017TEAS PETITION TO AMEND BASIS RECEIVED
Tuesday, March 14, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 10, 2017EXTENSION 1 GRANTED
Friday, March 10, 2017EXTENSION 1 FILED
Friday, March 10, 2017TEAS EXTENSION RECEIVED
Tuesday, November 1, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 6, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 6, 2016PUBLISHED FOR OPPOSITION
Wednesday, August 17, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, August 3, 2016LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, August 2, 2016ASSIGNED TO LIE
Thursday, July 21, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, July 15, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 14, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 14, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, February 8, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 8, 2016NON-FINAL ACTION E-MAILED
Monday, February 8, 2016NON-FINAL ACTION WRITTEN
Monday, February 8, 2016ASSIGNED TO EXAMINER
Tuesday, January 26, 2016NOTICE OF PSEUDO MARK E-MAILED
Monday, January 25, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, January 22, 2016NEW APPLICATION ENTERED IN TRAM